Daiichi Sankyo to commercialize Inspirion's anti-abuse opioid in the US

By Gareth Macdonald contact

- Last updated on GMT

iStock/zakaz86
iStock/zakaz86

Related tags: Opioid

Daiichi Sankyo will commercialize an abuse-deterrent formulation of the opioid painkiller morphine sulphate in the US in an agreement with developer Inspirion Delivery Sciences.

The deal will see Japan’s Daiichi sell MorphaBond in the US in return for an upfront fee and royalty payments. The firm will also commercialize a second undisclosed opioid product if it goes on to be approved by the US Food and Drug Administration (FDA).

Both drugs use Inspirion’s SentryBond anti-abuse technology, which is designed to make pills resistant to cutting, crushing, or breaking. In addition, when the pills are subjected to a liquid environment they form a viscous material that resists passage through a needle.

MorphaBond was approved by the FDA in 2015​ for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

US opioid abuse

Concerns about the misuse of opioid medications in the US have increased significantly in recent years.

To address this, the US FDA has encouraged drug firms to use anti-abuse technologies to try and prevent misuse.

In April last year the agency released final guidance​ explaining to manufacturers how to conduct studies to demonstrate that an opioid formulation has abuse-deterrent properties.

The abuse deterrent properties suggested by the FDA include physical and chemical barriers to abuse, agonist/antagonist combinations, aversion techniques to create unpleasant effects if a dosage form is manipulated and prodrugs.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers